Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Noted that the SP is now back to the price when the chairmen recently topped up his holding.More patience may be required to breach £1.00.
Wouldn’t be surprised if executive chair ,NR is guiding Volex to a £1 billion market capitalisation over a couple of years.Since he has taken over the reins Volex has gone from strength to strength using his contacts, acquisitions and organic growth. All divisions have performed exceptionally well.
Gilead have off-loaded ~ 18m shares! Down from 12% to 1%. Interesting....
EKF Diagnostics are another player in the C19 field but doesn’t seems to have appreciated in value versus ODX and NCYT.
Been following this share now for a couple of years and it appears range bound 150 to 190 apart from pandemic period.Only thing in its favour is the dividend.The CFO is leaving and no replacement has been announced. It is cash generative and may be attractive to a bigger player.
I’m expecting dividend payments to resume and also with possibility of 2nd wave infection,
sales may increase . Hopefully a rising SP will signal a recovery in the business.
Guidance from company at full year results was for good progress in 2020 and again re iterated in trading update in April.
Since then due to Covid-19 ,press have reported numerous outbreaks of infection and temporary closures at meat processing plants in USA and EU. Company hasn’t commented on this with an update ?
Some institutional investors have reduced their holdings. Others may see this as an opportunity.
There is doubt over the “suspended 6.3 p “ dividend being paid as it is under review.
SP has dropped ~ 30 % over three weeks.....interim results due end of July.
Looks as if current buyers of these shares will benefit from a good dividend payment....better than anything on the high street, as current guidance is for good progress on sales.
More patience may be required. Institutional investors are adding and would expect sales will continue increasing .Directors have been buying after their Covid update.
Devro has been a poor investment for long term holders with the SP on a downward trajectory The dividend does not compensate for the potential loss of capital.
Investors such as Blackmoor and Odyssean have bought in hoping for a turnaround in performance. With its SP in the doldrums perhaps an opportunist bid from CWK or Viscofan may be in the offing .